all-cis-docosa-4,7,10,13,16,19-hexaenoic acid/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on adverse event occurrence (oral or enteral supplement)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Overall, there were no significant differences in the incidence, type, or severity of adverse effects reported in the placebo or DHA group.”
Quoted verbatim from Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.. - Study
- RCT
- Duration
- 4 months
- Dose
- 4.4 g/day DHA-enriched algae triacylglycerol (11 x 400 mg capsules/day), oral, concurrent with 6 cycles (18 weeks) of neoadjuvant chemotherapy
- Population
- women with stage I-III non-metastatic breast cancer undergoing neoadjuvant chemotherapy
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.2025PMID:40490846Industry fundedPermalink
Keep reading
- Everything the graph holds on all-cis-docosa-4,7,10,13,16,19-hexaenoic acid
- Every compound studied against Adverse event occurrence (oral or enteral supplement)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M1B5X2ZRZ5Z1PGTG5353RBPN